Titer– tag –
-
Lonza Presents Optimization Strategies to Address Purity and Potency Challenges in In Vivo Lentiviral Vector Development for Cell and Gene Therapies
Biocompare Switzerland Overview Lonza outlined optimization strategies for lentiviral vector (LVV) development for in vivo delivery of cell and gene therapies. Key challenges in LVV development include achieving purity, complexity of val... -
VIVEbiotech Reaches 15 In Vivo Lentiviral Vector Programs, Fortifying Gene Therapy Manufacturing Leadership
BioPharma BoardRoom スペイン Overview VIVEbiotech has significantly advanced its position in gene therapy manufacturing by adding its 15th in vivo lentiviral vector (LVV) therapeutic program. This milestone underscores the company's robu... -
Lonza Emphasizes End-to-End Process Scalability for High-Titer AAV Production Using HEK293 Media
Lonza Switzerland Overview Lonza underscores the critical importance of end-to-end process scalability for high-titer AAV production utilizing HEK293 media. The article highlights the pivotal role of benchtop stirred-tank bioreactors in ... -
Next-Gen Process Analytics and QC Elevate Bioprocessing Efficiency: Real-Time Raman Probes Enable Continuous Glucose and Lactate Monitoring
Technology Networks UK Overview A Technology Networks article highlights how next-generation Process Analytical Technology (PAT) and industrial Quality Control (QC) testing significantly enhance biopharmaceutical manufacturing efficiency...
12